

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Alpelisib in combination with fulvestrant for treating
advanced hormone-receptor positive, HER2-negative,
PIK3CA-mutated breast cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

No equality issues have been identified.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

N/A

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

N/A

- | |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
|--|

N/A

Approved by Associate Director (name): Henry Edwards

Date: 13/05/21